2
Announcements
Trials
Browse
Landscape
Status
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
311
Leukemia, Lymphocytic, Chronic, B-Cell
108
Myelodysplastic Syndromes
63
Recurrence
55
Leukemia
43
Neoplasms
42
Precursor Cell Lymphoblastic Leukemia-Lymphoma
41
Lymphoma, Non-Hodgkin
41
Lymphoma, Mantle-Cell
32
Multiple Myeloma
28
Lymphoma, Large B-Cell, Diffuse
27
Leukemia, Myelomonocytic, Chronic
27
Lymphoma, Follicular
22
Lymphoma
21
Hematologic Neoplasms
20
Lymphoma, B-Cell, Marginal Zone
18
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
17
Leukemia, Biphenotypic, Acute
16
Burkitt Lymphoma
16
Myeloproliferative Disorders
11
Lymphoma, B-Cell
11
Leukemia, Myeloid
11
Neoplasm, Residual
10
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Waldenstrom Macroglobulinemia
9
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
7
Chromosome 17 deletion
6
Leukemia, B-Cell
5
Immunoglobulin Light-chain Amyloidosis
5
Breast Neoplasms
5
Interventions
Dexamethasone
10
fludarabine phosphate
9
Melphalan
9
fludarabine
8
Whole-Body Irradiation
7
Peripheral Blood Stem Cell Transplantation
7
Lenalidomide
7
Cyclophosphamide
7
Mycophenolic Acid
6
Bortezomib
6
Tacrolimus
5
Calcium Dobesilate
4
filanesib
3
dexamethasone acetate
3
dexamethasone 21-phosphate
3
daratumumab
3
carfilzomib
3
auricularum
3
Stem Cell Transplantation
3
Sirolimus
3
Filgrastim
3
liposomal doxorubicin
2
ixazomib
2
Steroids
2
Injections, Subcutaneous
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
Cytarabine
2
Cyclosporine
2
Carmustine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Plasma Cell
×
venetoclax
×
Clear all
NCT03123029
2026-01-30
Expanded Access to Venetoclax
AbbVie
Available